Hemophilia A treatment options

Hemophilia A: Recombinant Factor VIII (rFVIII) Treatment Options

rFVIII Products Available from Canadian Blood Services1

ADYNOVATE®

Antihemophilic Factor (Recombinant), PEGylated

ELOCTATE® (only available under selective criteria)

Antihemophilic Factor (Recombinant), Fc Fusion Protein

JIVI® (only available under selective criteria)

Antihemophilic Factor (Recombinant, B-domain deleted, PEGylated)

KOVALTRY®

Antihemophilic Factor (Recombinant)

NUWIQ®

Antihemophilic Factor (Recombinant, B-Domain deleted)

XYNTHA®

Antihemophilic Factor (Recombinant, B-Domain deleted)

Choose a category to compare treatment options.

rFVIII Treatment Option Select Category
ADYNOVATE® Chinese Hamster Ovary (CHO) All2 BAXJECT II Hi-Flow + 3000 IU
2 or 5 mL (depending on vial)
PEGylation
(PS80)
ELOCTATE® Human Embryonic Kidney (HEK) All3 PFS and Vial Adapter + 750, 1500 and 3000 IU
3 mL
Fc Fusion
(PS80)
JIVI® Baby Hamster Kidney (BHK) ≥12 years of age4 PFS and Vial Adapter + 3000 IU
2.5 mL
PEGylation
(PS80)
KOVALTRY® Baby Hamster Kidney (BHK) All5 PFS and Vial Adapter + 3000 IU
2.5 or 5 mL (depending on vial)
No Fusion or PEGylation
(PS80)
NUWIQ® Human Embryonic Kidney (HEK) All6 PFS and Vial Adapter + 2500, 3000 and 4000 IU
2.5 mL
No Fusion or PEGylation
(PS188)
XYNTHA® Chinese Hamster Ovary (CHO) All7 PFS and Vial Adapter or Solofuse + 3000 IU
4 mL
No Fusion or PEGylation
(PS80)
ADYNOVATE® ELOCTATE® JIVI® KOVALTRY® NUWIQ® XYNTHA®
Cell line Chinese Hamster Ovary (CHO) Human Embryonic Kidney (HEK) Baby Hamster Kidney (BHK) Baby Hamster Kidney (BHK) Human Embryonic Kidney (HEK) Chinese Hamster Ovary (CHO)
On‑demand
Prophylaxis
Age Groups All2 All3 ≥12 years of age4 All5 All6 All7
Reconstitution device BAXJECT II Hi-Flow PFS and Vial Adapter PFS and Vial Adapter PFS and Vial Adapter PFS and Vial Adapter PFS and Vial Adapter or Solofuse
Available sizes (250, 500, 1000 and 2000 IU) + 3000 IU + 750, 1500 and 3000 IU + 3000 IU + 3000 IU + 2500, 3000 and 4000 IU + 3000 IU
Diluent volume
2 or 5 mL (depending on vial)
3 mL
2.5 mL
2.5 or 5 mL (depending on vial)
2.5 mL
4 mL
rFVIII modification PEGylation Fc Fusion PEGylation No Fusion or PEGylation No Fusion or PEGylation No Fusion or PEGylation
Contains non‑medicinal polysorbate or poloxamer (types of PEG)
(PS80)
(PS80)
(PS80)
(PS80)
(PS188)
(PS80)

Download the Treatment Options PDF

The comparative information provided in the table above does not convey the relative effectiveness and/or safety of the listed products. As with all treatment options, your licensed healthcare professional must determine what therapy is appropriate for you based on their assessment of your individual treatment needs and goals.

† Prophylaxis is a course of treatment to prevent bleeds.

IU = international units; P188 = poloxamer 188; PFS = pre-filled syringe; PS80 = polysorbate 80

  1. Available from: https://www.hemophilia.ca/files/CBS%20announces%202018-2020%20contracts.pdf
  2. Adynovate Product Monograph. Shire Pharma Canada ULC (now part of Takeda Canada Inc.) May 1, 2020.
  3. Eloctate Product Monograph. Bioverativ Canada Inc. November 21, 2019.
  4. JIVI Product Monograph. Bayer Inc. October 18, 2018.
  5. Kovaltry Product Monograph. Bayer Inc. June 28, 2019.
  6. Nuwiq Product Monograph. Octapharma Canada Inc. December 14, 2018.
  7. Xyntha Product Monograph. Pfizer Canada Inc. May 11, 2016.
ADYNOVATE is a trademark or registered trademark of Baxalta Incorporated, a Takeda company.
ELOCTATE is a trademark or registered trademark of Bioverativ Therapeutics Inc., an affiliate of Sanofi.
JIVI is a registered trademark of Bayer Inc.
KOVALTRY is a registered trademark of Bayer Inc.
NUWIQ is a registered trademark of Octapharma AG.
XYNTHA is a registered trademark of Wyeth LLC, owner/Pfizer Canada Inc., Licensee.